Total Payments
$4,540
2021 Payments
$11.92
Companies
42
Transactions
215
Medicare Patients
4,580
Medicare Billing
$1.5M
Payment Breakdown by Category
Food & Beverage$3,216 (70.8%)
Consulting$1,200 (26.4%)
Education$123.42 (2.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,216 | 209 | 70.8% |
| Consulting Fee | $1,200 | 2 | 26.4% |
| Education | $123.42 | 4 | 2.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,318 | 12 | $0 (2020) |
| Janssen Biotech, Inc. | $395.17 | 27 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $318.91 | 20 | $0 (2018) |
| Genentech USA, Inc. | $287.68 | 22 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $255.95 | 17 | $0 (2020) |
| PFIZER INC. | $212.62 | 16 | $0 (2019) |
| Celgene Corporation | $139.46 | 8 | $0 (2019) |
| TESARO, Inc. | $130.08 | 5 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $122.65 | 8 | $0 (2019) |
| AbbVie, Inc. | $115.50 | 8 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $1,180 | 4 | AstraZeneca Pharmaceuticals LP ($1,138) |
| 2019 | $862.28 | 45 | Janssen Biotech, Inc. ($182.72) |
| 2018 | $917.49 | 48 | Janssen Biotech, Inc. ($91.25) |
| 2017 | $1,568 | 117 | Novartis Pharmaceuticals Corporation ($262.81) |
All Payment Transactions
215 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 12/17/2020 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,137.50 | General |
| Category: Oncology | ||||||
| 08/20/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $11.75 | General |
| Category: Oncology | ||||||
| 03/04/2020 | Dova Pharmaceuticals | Doptelet (Drug) | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: Hematology/Oncology | ||||||
| 02/26/2020 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $10.99 | General |
| Category: Oncology | ||||||
| 12/21/2019 | Janssen Biotech, Inc. | Balversa (Drug) | Food and Beverage | In-kind items and services | $4.26 | General |
| Category: Oncology | ||||||
| 11/21/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $24.78 | General |
| Category: Oncology | ||||||
| 10/22/2019 | Teva Pharmaceuticals USA, Inc. | BENDEKA (Drug) | Food and Beverage | In-kind items and services | $15.12 | General |
| Category: Oncology | ||||||
| 09/18/2019 | Genentech USA, Inc. | VENCLEXTA (Biological) | Food and Beverage | In-kind items and services | $13.95 | General |
| Category: BioOncology | ||||||
| 09/11/2019 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $21.83 | General |
| Category: Oncology | ||||||
| 08/20/2019 | Puma Biotechnology, Inc. | Nerlynx (Drug) | Food and Beverage | In-kind items and services | $20.76 | General |
| Category: Oncology | ||||||
| 07/30/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: ONCOLOGY | ||||||
| 07/24/2019 | Janssen Biotech, Inc. | Balversa (Drug) | Food and Beverage | In-kind items and services | $11.89 | General |
| Category: Oncology | ||||||
| 07/16/2019 | Janssen Biotech, Inc. | Erleada (Drug), DARZALEX | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Oncology | ||||||
| 07/09/2019 | Lilly USA, LLC | ERBITUX (Drug), CYRAMZA | Food and Beverage | In-kind items and services | $10.87 | General |
| Category: Oncology | ||||||
| 07/03/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.77 | General |
| Category: Oncology | ||||||
| 06/10/2019 | AbbVie, Inc. | Venclexta (Drug) | Education | In-kind items and services | $14.80 | General |
| Category: Virology | ||||||
| 06/04/2019 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $15.11 | General |
| Category: Virology | ||||||
| 06/04/2019 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $11.50 | General |
| Category: Oncology | ||||||
| 05/29/2019 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $13.38 | General |
| Category: Hematology/Oncology | ||||||
| 05/15/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LENVIMA | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: ONCOLOGY | ||||||
| 05/14/2019 | SANOFI-AVENTIS U.S. LLC | JEVTANA (Drug) | Education | In-kind items and services | $84.95 | General |
| Category: ONCOLOGY | ||||||
| 05/13/2019 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $23.13 | General |
| Category: Hematology / Oncology | ||||||
| 05/08/2019 | Bayer HealthCare Pharmaceuticals Inc. | Xofigo (Drug) | Food and Beverage | In-kind items and services | $24.72 | General |
| Category: Oncology | ||||||
| 04/29/2019 | GENZYME CORPORATION | LIBTAYO (Drug) | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 36 | 1,159 | 46,274 | $4.0M | $1.0M |
| 2022 | 34 | 1,033 | 7,960 | $528,194 | $91,458 |
| 2021 | 43 | 1,979 | 29,781 | $1.6M | $337,107 |
| 2020 | 9 | 409 | 607 | $81,572 | $29,400 |
Total Patients
4,580
Total Services
84,622
Medicare Billing
$1.5M
Procedure Codes
122
All Medicare Procedures & Services
122 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 13 | 13,400 | $2.0M | $552,420 | 28.2% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 11 | 9,180 | $1.3M | $348,470 | 27.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 122 | 403 | $94,234 | $25,930 | 27.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 75 | 222 | $152,292 | $21,811 | 14.3% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 13 | 12,750 | $63,750 | $10,995 | 17.2% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 19 | 5,980 | $53,820 | $8,234 | 15.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 20 | 123 | $28,905 | $6,709 | 23.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 47 | 47 | $23,923 | $4,843 | 20.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 39 | 55 | $18,160 | $4,715 | 26.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 25 | 35 | $10,920 | $3,215 | 29.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 30 | 45 | $10,485 | $3,007 | 28.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 58 | 252 | $26,460 | $2,964 | 11.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 74 | 278 | $17,236 | $2,869 | 16.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 35 | 61 | $18,544 | $2,829 | 15.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 29 | 29 | $9,686 | $2,426 | 25.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 79 | 286 | $5,434 | $2,396 | 44.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 16 | 48 | $16,032 | $2,395 | 14.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 79 | 310 | $10,850 | $2,347 | 21.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 18 | $11,016 | $2,315 | 21.0% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 13 | 15 | $7,845 | $2,049 | 26.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 37 | 74 | $11,248 | $1,621 | 14.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 27 | 73 | $11,388 | $1,576 | 13.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 23 | 90 | $8,370 | $958.68 | 11.5% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 31 | 59 | $3,422 | $788.24 | 23.0% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 17 | 106 | $48,972 | $731.89 | 1.5% |
About Dr. Keith Goldstein, M.D
Dr. Keith Goldstein, M.D is a Medical Oncology healthcare provider based in Eugene, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1861462566.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Keith Goldstein, M.D has received a total of $4,540 in payments from pharmaceutical and medical device companies, with $11.92 received in 2021. These payments were reported across 215 transactions from 42 companies. The most common payment nature is "Food and Beverage" ($3,216).
As a Medicare-enrolled provider, Goldstein has provided services to 4,580 Medicare beneficiaries, totaling 84,622 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 122 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Eugene, OR
- Active Since 01/25/2006
- Last Updated 08/04/2021
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1861462566
Products in Payments
- CALQUENCE (Drug) $1,149
- OPDIVO (Biological) $217.57
- IMBRUVICA (Drug) $169.85
- DARZALEX (Biological) $162.12
- JEVTANA (Drug) $140.40
- ZEJULA (Drug) $106.23
- KEYTRUDA (Biological) $96.65
- Venclexta (Drug) $85.71
- KISQALI (Drug) $83.06
- TECENTRIQ (Biological) $82.96
- VENCLEXTA (Biological) $77.11
- JADENU (Drug) $77.02
- Halaven (Drug) $76.22
- Revlimid (Drug) $71.66
- ADCETRIS (Biological) $68.09
- TASIGNA (Drug) $65.88
- TAGRISSO (Drug) $64.89
- ELIQUIS (Drug) $61.84
- Avastin (Biological) $59.03
- Neulasta (Biological) $53.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.